
|Videos|November 18, 2021
Current clinical trials examining LuPSMA
Author(s)Urology Times staff
“There's a hope that we can modulate PSMA expression with some drugs, increase the amount of PSMA on the tumors, [and] therefore increase the amount of radiation that we can target,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
Advertisement
In this video, Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, discusses the current clinical trials highlighted in the lecture, “LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer,” presented recently at the 2021 Prostate Cancer Foundation Scientific Retreat. Hofman is a nuclear medicine physician and director of PROSTIC, Melbourne, Australia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










